International Journal of Medicine and Data
International Journal of Medicine and Data. 2022; 6: (6) ; 10.12208/j.ijmd.20220262 .
总浏览量: 313
贵州中医药大学第二附属医院 贵州贵阳
*通讯作者： 章红玉,单位：贵州中医药大学第二附属医院 贵州贵阳；
宫颈癌高居全世界高居妇女癌症的第二位。宫颈癌的发生和许多危险因子有关，研究指出高危型人乳头状瘤病毒（HPV）持续感染是导致宫颈病变与宫颈癌发病及其治疗后复发的主要原因。临床与相关文献均指出抗HPV生物功能敷料的应用是早期预防与减缓癌症的有效方式之一，可以作为一级预防疫苗有效补充。本研究主要目的是通过比较高危型人乳头状瘤病毒持续感染的清除方法，介绍香妃绀扰嗉抗HPV生物功能敷料在预防宫颈癌的潜能，其广谱抗菌性和低耐药性，抗癌、抗病毒、抗寄生虫和调节免疫等诸多作用，超限年龄无法打宫颈癌疫苗人群可以采用香妃绀扰嗉提高免疫力减少宫颈癌发生率，该方法具有巨大的医学应用前景。
Cervical cancer is the second most common cancer in women with high profile. The occurrence of cervical cancer is related to various risk factors. Studies have shown that persistent infection of high human papilloma (HPV) is a major drug resistance method that leads to cervical lesions and cervical cancer and its recurrence after treatment. The average application of HPV and related literature reports is an effective way to apply early preventive drugs and chicken protein products, which can be used as an effective method. Regular removal method, its tumor antibacterial agent cyanosis HPV protein particles infecting cervical cancer, broad-spectrum antibacterial agent cyanosis cervical cancer antibody, resistance and anti-infective.,Xiangfei Interferon can be used to improve the incidence of immune uterus, and the method has medical advantages.This method has great prospects for medical applications.
[1] A randomized open-label clinical trial of an anti-HPV biological dressing （JB01-BD）administered intravaginally to treat high-risk HPV infection [J] . Xuetao Guo,Lixia Qiu,Yue Wang,Yonghong Wang,Qian Wang,Lei Song,Yali Li,Ke Huang,Xinxin Du,Wensheng Fan,Shufang Jiang,Qianqing Wang,Haoyang Li,Yi Yang,Yuanguang Meng,Yun Zhu,Lu Lu,Shibo Jiang. Microbes and Infection . 2015
[2] Chemically modified bovine beta- lactoglobulin inhibits human papillomavirus infection [J] . Lu Lu,Xia Yang,Yuan Li,Shibo Jiang. Microbes and Infection . 2013 (6-7)
[3] Human papillomavirus is a necessary cause of invasive cervical cancer worldwide [J] . J. Pathol. . 1999 (1)
[4] 与宫颈癌相关的人乳头瘤病毒的持续感染与免疫逃逸[J].曹雪芹,黄庆华,李雍龙. 国外医学.病毒学分册. 2005(06)
[5] 人乳头瘤病毒感染与宫颈疾病的关系[J]. 王晓芳,刘静. 天津医药. 1999(05)
[6] 人乳头瘤病毒疫苗研究新进展[J]. 欧阳婧华. 中国医疗前沿. 2009(23)
[7] 宫颈的解剖与生理[J]. 薛凤霞,成争先. 中国实用妇科与产科杂志. 2004(07)
[8] 人乳头瘤病毒16型感染与机体免疫[J]. 郝敏,卞美璐. 中日友好医院学报. 2009(02)
[9] 宫颈癌人乳头瘤病毒疫苗的研究进展[J]. 林海英,付晓丹,罗桂晶,张玉泉. 中国实用妇科与产科杂志. 2007(06)
[10] 宫颈癌患者心理状况及影响因素分析[J]. 饶小卫,谢满,曾爱群,黄小梅,温盛英,陈小兰,李金伟,吴修洪. 赣南医学院学报. 2008(06)
[11] A randomized open-label clinical trial of an anti-HPV biological dressing （JB01-BD）administered intravaginally to treat high-risk HPV infection [J] . Xuetao Guo,Lixia Qiu,Yue Wang,Yonghong Wang,Qian Wang,Lei Song,Yali Li,Ke Huang,Xinxin Du,Wensheng Fan,Shufang Jiang,Qianqing Wang,Haoyang Li,Yi Yang,Yuanguang Meng,Yun Zhu,Lu Lu,Shibo Jiang. Microbes and Infection . 2015
[12] Comparative immunogenicity and safety of human papillomavirus （HPV）-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14?years: Results to month 12 from a randomized trial [J] . Ting Fan Leung,Anthony Pak-Yin Liu,Fong Seng Lim,Franck Thollot,Helen May Lin Oh,Bee Wah Lee,Lars Rombo,Ngiap ChuanTan,Roman Rouzier,Damien Friel,Benoit De Muynck,Stéphanie De Simoni,Pemmaraju Suryakiran,Marjan Hezareh,Nicolas Folschweiller,Florence Thomas,Frank Struyf. Human Vaccines ＆ Immunotherapeutics . 2015 (7)
[13] Twist-related protein 1-mediated regulation of mesenchymal change contributesto the migration and invasion of cervical cancer cells [J]. Danqing Wang,Qingli Li,Kemin Li,Ping Xiao,Rutie Yin. Oncology Letters . 2015 (5)
[14] EMT in cervical cancer: Its role in tumour progression and response to therapy [J] . Rehana Qureshi,Himanshu Arora,M.A. Rizvi. Cancer Letters . 2014